Payment overview · 2025
General Payments
$146.63
7 reported records · 6 companies
Healthcare provider profile · identity verified
Daniel Benson, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SAINT JOSEPH, MI · NPI 1851770465
Verified facts
What the public records show
CMS Open Payments records show Daniel Benson, D.O. received $146.63 in general payments during 2025 across 7 reported records.
Hologic Sales and Service, LLC accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $47.32 | 32.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.81 | 19.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.51 | 14.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.07 | 11.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.56 | 11.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.36 | 10.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.63 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CoolSeal Generator Normalized: coolseal generator |
Device | Hologic Sales and Service, LLC | $47.32 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.81 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.81 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 544 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 436 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 425 | 118 |
| Lisinopril | Lisinopril | 414 | 117 |
| Losartan Potassium | Losartan Potassium | 358 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 222 | 60 |
| Simvastatin | Simvastatin | 217 | 65 |
| Metformin Hcl | Metformin Hcl | 210 | 60 |
| Gabapentin | Gabapentin | 204 | 33 |
| Omeprazole | Omeprazole | 195 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 17 |
| Farxiga | Dapagliflozin Propanediol | 126 | 27 |
| Sertraline Hcl | Sertraline Hcl | 122 | 34 |
| Furosemide | Furosemide | 113 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 37 |
| Alendronate Sodium | Alendronate Sodium | 106 | 36 |
| Jardiance | Empagliflozin | 102 | 24 |
| Allopurinol | Allopurinol | 100 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 26 |
| Meloxicam | Meloxicam | 93 | 29 |
| Tramadol Hcl | Tramadol Hcl | 84 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 21 |
| Trazodone Hcl | Trazodone Hcl | 79 | 22 |
| Chlorthalidone | Chlorthalidone | 74 | 21 |
| Finasteride | Finasteride | 73 | 22 |
| Eliquis | Apixaban | 71 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 13 |
| Montelukast Sodium | Montelukast Sodium | 64 | 18 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Pregabalin | Pregabalin | 60 | suppressed |
| Ozempic | Semaglutide | 56 | suppressed |
| Potassium Chloride | Potassium Chloride | 55 | 16 |
| Prednisone | Prednisone | 54 | 46 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 16 |
| Metformin Hcl Er | Metformin Hcl | 47 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | suppressed |
| Atenolol | Atenolol | 44 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 13 |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Carvedilol | Carvedilol | 34 | 14 |
| Spironolactone | Spironolactone | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | 11 |
| Valsartan | Valsartan | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.63 · 7 records | Hologic Sales and Service, LLC | CoolSeal Generator, EVENITY, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, UBRELVY, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error